Why I am Buying XF1 (XREF), page-34

First 34 Last

Share
Profile

Follow
enoinvest

185 Posts.

11

13/08/20

15:24

Post #: 46514918
Share

Originally posted by T.E.P.: ↑

That's not my investment thesis but I agree that a long term hold has the potential for extreme upside.

Any COVID pain that was experienced across the past few months (even though XF1 did well during this time with their 2nd largest sales quarter ever) is akin to pulling back a string on a bow and arrow. For every lost job in the economy across the past few months, there will be a time in the future where those jobs return. XF1 can benefit tremendously from turnover.

My investment thesis is that XF1 is in the process of a re-rate to historical levels as the market recognises that management have delivered on what they said they would do -- bring the company to cashflow positive operations while maintaining growth. The next 2 quarters are key. They also have funding (if required) from Pure Asset Management in place. I think investors here will be rewarded massively on a short term horizon and a long time horizon. Current levels are less than 50% of what the company has been valued at historically, yet the company has never been stronger nor leaner from a cashflow perspective.

Ord Minnett estimated Xref's lifetime customer value to customer acquisition cost ratio (LTV/CAC) to be ~6x. That is outstanding -- more than double the SaaS industry benchmark of 3x. With costs guided to remain controlled and XRef improving its sales cycle significantly, I can see this ratio improving on the medium term. Post breakeven, XRef is set up for excellent operating leverage. Ord Minnett estimates long term reported EBITDA margins of ~49%.

This is a no brainer for me at these levels. Whether you hold for 6 weeks, 6 months or 6 years.

T.E.P.

Expand

I bought today. I hope it doubles in the short term

XF1 Price at posting: 19.5¢ Sentiment: Buy Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 37 more messages in this thread...

First 34 Last

Add XF1 (ASX) to my watchlist

(20min delay)
Last 14.0¢		Change -0.010(6.67%)		Mkt cap ! $26.47M

Open	High	Low	Value	Volume
14.0¢	14.0¢	14.0¢	$6.693K	47.80K

Buyers (Bids)

No.	Vol.	Price($)
1	73553	14.0¢

Sellers (Offers)

Price($)	Vol.	No.
15.0¢	1630	1

View Market Depth

No.	Vol.	Price($)
1	73553	0.140
1	100000	0.130
1	8325	0.120
1	9095	0.110
1	9525	0.105

Price($)	Vol.	No.
0.150	1630	1
0.165	17981	1
0.170	50000	2
0.180	47000	2
0.190	37375	2

Last trade - 14.45pm 02/10/2024 (20 minute delay)

XF1 (ASX) Chart

Why I am Buying XF1 (XREF), page-34

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why I am Buying XF1 (XREF), page-34

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News